Cargando…
Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to q...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516243/ https://www.ncbi.nlm.nih.gov/pubmed/27706836 http://dx.doi.org/10.1002/hep.28860 |
_version_ | 1783251129708052480 |
---|---|
author | Decaris, Martin L. Li, Kelvin W. Emson, Claire L. Gatmaitan, Michelle Liu, Shanshan Wang, Yenny Nyangau, Edna Colangelo, Marc Angel, Thomas E. Beysen, Carine Cui, Jeffrey Hernandez, Carolyn Lazaro, Len Brenner, David A. Turner, Scott M. Hellerstein, Marc K. Loomba, Rohit |
author_facet | Decaris, Martin L. Li, Kelvin W. Emson, Claire L. Gatmaitan, Michelle Liu, Shanshan Wang, Yenny Nyangau, Edna Colangelo, Marc Angel, Thomas E. Beysen, Carine Cui, Jeffrey Hernandez, Carolyn Lazaro, Len Brenner, David A. Turner, Scott M. Hellerstein, Marc K. Loomba, Rohit |
author_sort | Decaris, Martin L. |
collection | PubMed |
description | Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and noninvasively in blood. Twenty‐one patients with suspected NAFLD ingested heavy water ((2)H(2)O, 50‐mL aliquots) two to three times daily for 3‐5 weeks prior to a clinically indicated liver biopsy. Liver collagen fractional synthesis rate (FSR) and plasma lumican FSR were measured based on (2)H labeling using tandem mass spectrometry. Patients were classified by histology for fibrosis stage (F0‐F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH). Magnetic resonance elastography measurements of liver stiffness were also performed. Hepatic collagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score and liver stiffness) and correlated with hemoglobin A1C. In addition, plasma lumican FSR demonstrated a significant correlation with hepatic collagen FSR. Conclusion: Using a well‐characterized cohort of patients with biopsy‐proven NAFLD, this study demonstrates that hepatic scar in NASH is actively remodeled even in advanced fibrosis, a disease that is generally regarded as static and slowly progressive. Moreover, hepatic collagen FSR correlates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR correlates with hepatic collagen FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis in humans. (Hepatology 2017;65:78‐88). |
format | Online Article Text |
id | pubmed-5516243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55162432017-08-02 Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood Decaris, Martin L. Li, Kelvin W. Emson, Claire L. Gatmaitan, Michelle Liu, Shanshan Wang, Yenny Nyangau, Edna Colangelo, Marc Angel, Thomas E. Beysen, Carine Cui, Jeffrey Hernandez, Carolyn Lazaro, Len Brenner, David A. Turner, Scott M. Hellerstein, Marc K. Loomba, Rohit Hepatology Steatohepatitis/Metabolic Liver Disease Excess collagen synthesis (fibrogenesis) in the liver plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD). Methods are needed to identify patients with more rapidly progressing disease and to demonstrate early response to treatment. We describe here a novel method to quantify hepatic fibrogenesis flux rates both directly in liver tissue and noninvasively in blood. Twenty‐one patients with suspected NAFLD ingested heavy water ((2)H(2)O, 50‐mL aliquots) two to three times daily for 3‐5 weeks prior to a clinically indicated liver biopsy. Liver collagen fractional synthesis rate (FSR) and plasma lumican FSR were measured based on (2)H labeling using tandem mass spectrometry. Patients were classified by histology for fibrosis stage (F0‐F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis (NASH). Magnetic resonance elastography measurements of liver stiffness were also performed. Hepatic collagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibrosis score and liver stiffness) and correlated with hemoglobin A1C. In addition, plasma lumican FSR demonstrated a significant correlation with hepatic collagen FSR. Conclusion: Using a well‐characterized cohort of patients with biopsy‐proven NAFLD, this study demonstrates that hepatic scar in NASH is actively remodeled even in advanced fibrosis, a disease that is generally regarded as static and slowly progressive. Moreover, hepatic collagen FSR correlates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR correlates with hepatic collagen FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis in humans. (Hepatology 2017;65:78‐88). John Wiley and Sons Inc. 2016-11-15 2017-01 /pmc/articles/PMC5516243/ /pubmed/27706836 http://dx.doi.org/10.1002/hep.28860 Text en © 2016 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Steatohepatitis/Metabolic Liver Disease Decaris, Martin L. Li, Kelvin W. Emson, Claire L. Gatmaitan, Michelle Liu, Shanshan Wang, Yenny Nyangau, Edna Colangelo, Marc Angel, Thomas E. Beysen, Carine Cui, Jeffrey Hernandez, Carolyn Lazaro, Len Brenner, David A. Turner, Scott M. Hellerstein, Marc K. Loomba, Rohit Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title_full | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title_fullStr | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title_full_unstemmed | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title_short | Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
title_sort | identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood |
topic | Steatohepatitis/Metabolic Liver Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516243/ https://www.ncbi.nlm.nih.gov/pubmed/27706836 http://dx.doi.org/10.1002/hep.28860 |
work_keys_str_mv | AT decarismartinl identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT likelvinw identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT emsonclairel identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT gatmaitanmichelle identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT liushanshan identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT wangyenny identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT nyangauedna identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT colangelomarc identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT angelthomase identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT beysencarine identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT cuijeffrey identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT hernandezcarolyn identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT lazarolen identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT brennerdavida identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT turnerscottm identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT hellersteinmarck identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood AT loombarohit identifyingnonalcoholicfattyliverdiseasepatientswithactivefibrosisbymeasuringextracellularmatrixremodelingratesintissueandblood |